



Brumpton, B., Fritsche, L. G., Zheng, J., Davey Smith, G., & Åsvold, B. O. (2019). Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. *Circulation: Genomic and Precision Medicine*, 12(1), 44-47.
<https://doi.org/10.1161/CIRCGEN.118.002335>

Peer reviewed version

License (if available):
Other

Link to published version (if available):
[10.1161/CIRCGEN.118.002335](https://doi.org/10.1161/CIRCGEN.118.002335)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the American Heart Association at <https://doi.org/10.1161/CIRCGEN.118.002335> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

